Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Doctors Hope for Entry of Major Pharmas into Generics Market: Survey
September 6, 2010
- IBD Market to Grow to US$5.6 Bil. in 2019: Datamonitor
September 6, 2010
- Kyowa Kirin Withdraws Application for KW-2246
September 6, 2010
- Questionnaires on Use of Generics to Be Reconsidered
September 6, 2010
- JPMA Calls For Reduction in Effective Corporate Tax Rate to Int'l Standard
September 6, 2010
- Average PMDA Staff Member Earns ¥7,223,000 per Year
September 6, 2010
- Kyowa Kirin Launches Nesp Inj. Plastic Syringe
September 6, 2010
- 3 Switch OTC Drugs Recommended for Approval
September 6, 2010
- Ain Pharmaciez to Strengthen Tie with 7&i HD
September 6, 2010
- General Consumers Show Great Interest in Switch OTC Drugs: JSMI Survey
September 6, 2010
- CDFS Withholds Recommendation of Approval for Liovel
September 6, 2010
- Sales of Class 1 OTC Drugs Up for the 1st Time since PAL Amendment: JSMI
September 6, 2010
- Treakisym from SymBio Recommended for Approval
September 6, 2010
- NEW PRODUCTS
September 6, 2010
- Chuikyo Recommends Reimbursement before Approval Based on Data from Public Domain
September 6, 2010
- Approval of Takepron for Prevention of Ulcers Is a Major Landmark: Prof. Sugano
September 6, 2010
- Korosho Considers Introduction of a CU System
September 6, 2010
- Fuso Applies for Buprenorphine for PHN
September 6, 2010
- MTPC Completes All-Patient PMS on Remicade for Uveoretinitis
September 6, 2010
- Nesina Approved for Combination with Actos: Takeda
September 6, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…